Yıl: 2023 Cilt: 5 Sayı: 1 Sayfa Aralığı: 13 - 22 Metin Dili: İngilizce DOI: 10.36519/idcm.2023.177 İndeks Tarihi: 12-05-2023

Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases

Öz:
Objective: Fournier’s gangrene (FG) is a rare necrotizing fasciitis affecting genital and peri- anal areas. This study aimed to provide data on predicting factors, mortality rates, and fac- tors affecting mortality in comparison of survivors and non-survivors in patients with FG. Materials and Methods: This study included a retrospective analysis of patients diagnosed with FG between 2008 and 2018. Results: A total of 97 patients with FG were included in this study. Of the patients, 72 (74%) were male. The mean age was 56.03±13.92 years, and the median was 57 (21-90). The mor- tality rate was 21.6%. The most frequently isolated microorganism from tissue and blood cultures was Escherichia coli (43%-42%). The median Fournier’s Gangrene Severity Index (FGSI) and Uludağ FGSI (UFGSI) scores were 4 (0-20) and 5 (1-22), respectively. In the univar- iate model, mortality risk increases 7.18 times (p=0.001) in patients with two or more co- morbidities, 1.31 times as the FGSI score increases (p<0.001), 1.28 times as the UFGSI score increases (p<0.001). When the cut-off value was set as 8 for the FGSI score, the sensitivity was 71.43%, and the specificity was 73.68%. The sensitivity was 73.43%, and the specificity was 75% when the cut-off value was set as 6 for the UFGSI score. In the univariate model, the mortality risk of those with hypotension was 6.07 times higher (p=0.003); as the platelet count increased, mortality risk decreased (odds ratio [OR]=0.99; p=0.02). The mortality risk of those hospitalized in the intensive care unit (ICU) was 16.5 times higher than those fol- lowed in the ward (p<0.001). In the multivariate model, this ratio was 6.49. Conclusion: We concluded that FGSI and UFGSI scores could be used to predict mortal- ity. Management of FG requires a multidisciplinary approach. Empiric treatment should include carbapenems and be de-escalated once getting the culture results. Authors from different centers should report their experiences to help reveal the ideal treatment and evaluate the consequences.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1 Mallikarjuna MN, Vijayakumar A, Patil VS, Shivswamy BS. Fournier’s gangrene: current practices. ISRN Surg. 2012;2012:942437. [CrossRef]
  • 2 Uluğ M, Gedik E, Girgin S, Çelen MK, Ayaz C. The evaluation of microbiology and Fournier’s gangrene severity index in 27 patients. Int J Infect Dis. 2009;13(6):e424-30. [CrossRef]
  • 3 Jeong HJ, Park SC, Seo IY, Rim JS. Prognostic factors in Fournier gangrene. Int J Urol. 2005;12(12):1041-4. [CrossRef]
  • 4 Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier’s gangrene. J Urol. 1995;154(1):89-92.
  • 5 Yilmazlar T, Ozturk E, Ozguc H, Ercan I, Vuruskan H, Oktay B. Fournier’s gangrene: an analysis of 80 patients and a novel scoring system. Tech Coloproctol. 2010;14(3):217-23. [CrossRef]
  • 6 Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Lab- oratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32(7):1535-41. [CrossRef]
  • 7 Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al; Infectious Diseases Society of America. Executive summary: practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;15;59(2):147-59. [CrossRef]
  • 8 Montrief T, Long B, Koyfman A, Auerbach J. Fournier gangrene: a review for emergency clinicians. J Emerg Med. 2019;57(4):488- 500. [CrossRef]
  • 9 Sparenborg JD, Brems JA, Wood AM, Hwang JJ, Venkatesan K. Fournier’s gangrene: a modern analysis of predictors of out- comes. Transl Androl Urol. 2019;8(4):374-8. [CrossRef]
  • 10 Eke N. Fournier’s gangrene: a review of 1726 cases. Br J Surg. 2000;87(6):718-28. [CrossRef]
  • 11 Canbaz H, Altun U, Dirlik M, Türkmenoğlu Ö, Taşdelen B, Aydın S. [Fournier’s gangrene: analysis of risk factors affecting the prognosis and cost of therapy in 18 cases]. Ulus Travma Acil Cerrahi Derg. 2010;16(1):71-6. Turkish.
  • 12 Czymek R, Frank P, Limmer S, Schmidt A, Jungbluth T, Roblick U, et al. Fournier’s gangrene: is the female gender a risk factor? Langenbecks Arch Surg. 2010;395(2):173-80. [CrossRef]
  • 13 Taviloglu K, Cabioglu N, Cagatay A, Yanar H, Ertekin C, Baspinar I, et al. Idiopathic necrotizing fasciitis: risk factors and strate- gies for management. Am Surg. 2005;71(4):315-20.
  • 14 Villanueva-Sáenz E, Martínez Hernández-Magro P, Valdés Ovalle M, Montes Vega J, Alvarez-Tostado F JF. Experience in management of Fournier’s gangrene. Tech Coloproctol. 2002;6(1):5-10; discussion 11-3. [CrossRef]
  • 15 Tenório CEL, Lima SVC, Albuquerque AV, Cavalcanti MP, Teles F. Risk factors for mortality in Fournier’s gangrene in a general hospital: use of simplified founier gangrene severe index score (SFGSI). Int Braz J Urol. 2018;44(1):95-101. [CrossRef]
  • 16 Misiakos EP, Bagias G, Patapis P, Sotiropoulos D, Kanavidis P, Machairas A. Current concepts in the management of necro- tizing fasciitis. Front Surg. 2014;29;1:36. [CrossRef]
  • 17 Sarkis P, Farran F, Khoury R, Kamel G, Nemr E, Biajini J, et al. [Fournier’s gangrene: a review of the recent literature]. Prog Urol 2009;19:75-84. French. [CrossRef]
  • 18 Goh T, Goh LG, Ang CH, Wong CH. Early diagnosis of necrotiz- ing fasciitis. Br J Surg. 2014;101(1):e119-25. [CrossRef]
  • 19 Dworkin MS, Westercamp MD, Park L, McIntyre A. The epidemi- ology of necrotizing fasciitis including factors associated with death and amputation. Epidemiol Infect. 2009;137(11):1609-14. [CrossRef]
  • 20 Hsiao CT, Weng HH, Yuan YD, Chen CT, Chen IC. Predictors of mortality in patients with necrotizing fasciitis. Am J Emerg Med. 2008;26(2):170-5. [CrossRef]
  • 21 Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiol- ogy, and determinants of mortality. J Bone Joint Surg Am. 2003;85(8):1454-60.
  • 22 Rello J, Valenzuela-Sánchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: a review of advances in management. Adv Ther. 2017;34(11):2393-411. [CrossRef]
  • 23 Thiery-Antier N, Binquet C, Vinault S, Meziani F, Bois- ramé-Helms J, Quenot JP; EPIdemiology of Septic Shock Group. Is thrombocytopenia an early prognostic marker in septic shock? Crit Care Med. 2016;44(4):764-72. [CrossRef]
  • 24 Stone HH, Martin JD Jr. Synergistic necrotizing cellulitis. Ann Surg. 1972;175(5):702-11. [CrossRef]
  • 25 Roghmann F, von Bodman C, Löppenberg B, Hinkel A, Palisaar J, Noldus J. Is there a need for the Fournier’s gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier’s gangrene. BJU Int. 2012;110(9):1359- 65. [CrossRef]
  • 26 Koukouras D, Kallidonis P, Panagopoulos C, Al-Aown A, Athanasopoulos A, Rigopoulos C, et al. Fournier’s gangrene, a urologic and surgical emergency: presentation of a multi-in- stitutional experience with 45 cases. Urol Int. 2011;86(2):167- 72. [CrossRef]
  • 27 Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, et al. Fournier’s gangrene: risk factors and strategies for man- agement. World J Surg. 2006;30(9):1750-4. [CrossRef]
  • 28 Voelzke BB, Hagedorn JC. Presentation and diagnosis of Fourni- er gangrene. Urology. 2018;114:8-13. [CrossRef]
  • 29 Louro JM, Albano M, Baltazar J, Vaz M, Diogo C, Ramos S, et al. Fournier’s gangrene: 10-year experience of a plastic surgery and burns department at a tertiary hospital. Acta Med Port. 2019;31;32(5):368-74. [CrossRef]
  • 30 Christaki E, Marcou M, Tofarides A. Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence. J Mol Evol. 2020;88(1):26-40. [CrossRef]
APA atilla a, Temoçin F, Kuruoglu T, Kamali Polat A (2023). Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. , 13 - 22. 10.36519/idcm.2023.177
Chicago atilla aynur,Temoçin Fatih,Kuruoglu Tuba,Kamali Polat Ayfer Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. (2023): 13 - 22. 10.36519/idcm.2023.177
MLA atilla aynur,Temoçin Fatih,Kuruoglu Tuba,Kamali Polat Ayfer Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. , 2023, ss.13 - 22. 10.36519/idcm.2023.177
AMA atilla a,Temoçin F,Kuruoglu T,Kamali Polat A Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. . 2023; 13 - 22. 10.36519/idcm.2023.177
Vancouver atilla a,Temoçin F,Kuruoglu T,Kamali Polat A Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. . 2023; 13 - 22. 10.36519/idcm.2023.177
IEEE atilla a,Temoçin F,Kuruoglu T,Kamali Polat A "Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases." , ss.13 - 22, 2023. 10.36519/idcm.2023.177
ISNAD atilla, aynur vd. "Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases". (2023), 13-22. https://doi.org/10.36519/idcm.2023.177
APA atilla a, Temoçin F, Kuruoglu T, Kamali Polat A (2023). Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. Infectious diseases and clinical microbiology (Online), 5(1), 13 - 22. 10.36519/idcm.2023.177
Chicago atilla aynur,Temoçin Fatih,Kuruoglu Tuba,Kamali Polat Ayfer Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. Infectious diseases and clinical microbiology (Online) 5, no.1 (2023): 13 - 22. 10.36519/idcm.2023.177
MLA atilla aynur,Temoçin Fatih,Kuruoglu Tuba,Kamali Polat Ayfer Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. Infectious diseases and clinical microbiology (Online), vol.5, no.1, 2023, ss.13 - 22. 10.36519/idcm.2023.177
AMA atilla a,Temoçin F,Kuruoglu T,Kamali Polat A Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. Infectious diseases and clinical microbiology (Online). 2023; 5(1): 13 - 22. 10.36519/idcm.2023.177
Vancouver atilla a,Temoçin F,Kuruoglu T,Kamali Polat A Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases. Infectious diseases and clinical microbiology (Online). 2023; 5(1): 13 - 22. 10.36519/idcm.2023.177
IEEE atilla a,Temoçin F,Kuruoglu T,Kamali Polat A "Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases." Infectious diseases and clinical microbiology (Online), 5, ss.13 - 22, 2023. 10.36519/idcm.2023.177
ISNAD atilla, aynur vd. "Fournier’s Gangrene: Microbiological Profile and Risk Factors for Mortality: Review of 97 Cases". Infectious diseases and clinical microbiology (Online) 5/1 (2023), 13-22. https://doi.org/10.36519/idcm.2023.177